OnDemand WTP Pricing Research

Potential Pricing of Peanut Allergy Treatments Too High, Report Says | BioSpace

With the ever-rising concerns over the costs of various prescription medications, a report from consumer pharmaceutical watchdog group Institute for Clinical and Economic Review (ICER) released a report questioning the potential pricing of two yet-to-be-approved peanut allergy treatments.

In March, the U.S. Food and Drug Administration accepted the Biologics License Application of Aimmune Therapeutics’s lead peanut allergy candidate, AR101. Aimmune’s product could be approved as a potential treatment to reduce the risk of anaphylaxis following accidental exposure to peanut. AR101 has been granted both Breakthrough Therapy Designation, as well as Fast Track Designation by the FDA. The company filed the BLA based on Phase III data that showed its peanut allergy therapy was effective in more than 67 percent of juvenile patients.

France-based DBV Technologies is aiming its Viaskin technology at multiple food allergies, such as milk and peanuts. In February, the company shared a post hoc analysis of its Phase III PEPITES study that showed 62.6 percent of patients who received Viaskin Peanut showed an increase in their eliciting dose at 12 months of treatment in comparison to placebo.

Read complete article here:

Potential Pricing of Peanut Allergy Treatments Too High, Report Says | BioSpace.

Post a Comment

WP-SpamFree by Pole Position Marketing